$3.69
Price
$399M
Market Cap
—
P/E Ratio
-3.0
Forward P/E
$-2.25
EPS (TTM)
—
Dividend Yield
$223M
Cash
$25M
Total Debt
108M
Shares Out
$2.19
$11.45
52-Week Range
Institutional Ownership of ROCKET PHARMACEUTICALS INC
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
| No funds currently hold this stock. | |||||
Trading Activity for ROCKET PHARMACEUTICALS INC
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| 2025-Q2 | |||||
| SELL | EXIT | — | — | $5.81 | |
| 2025-Q1 | |||||
| SELL | -3.9% | 117.3K | $782398 | $10.16 | |
| 2024-Q4 | |||||
| BUY | +66.3% | 122.1K | $2M | $15.67 | |
| 2024-Q3 | |||||
| BUY | +9.2% | 73.4K | $1M | $19.78 | |
| 2024-Q2 | |||||
| BUY | +10.3% | 67.2K | $1M | $22.86 | |
| 2024-Q1 | |||||
| BUY | +0.1% | 60.9K | $2M | $28.54 | |
| 2023-Q4 | |||||
| BUY | +1.1% | 60.9K | $2M | $21.35 | |
| 2023-Q3 | |||||
| BUY | +10.3% | 60.2K | $1M | $17.81 | |
| 2023-Q2 | |||||
| BUY | +0.6% | 54.6K | $1M | $20.67 | |
| 2023-Q1 | |||||
| SELL | -0.2% | 54.2K | $928994 | $19.62 | |
| 2022-Q4 | |||||
| BUY | NEW | 54.3K | $1M | $18.09 | |
| 2022-Q1 | |||||
| SELL | EXIT | — | — | $16.67 | |
| 2021-Q4 | |||||
| SELL | -3.5% | 36.4K | $796000 | $27.59 | |
| 2021-Q3 | |||||
| BUY | +1.1% | 37.8K | $1M | $34.74 | |
| 2021-Q2 | |||||
| BUY | +28.6% | 37.4K | $2M | $43.19 | |
| 2021-Q1 | |||||
| SELL | -15.7% | 29.1K | $1M | $55.16 | |
| 2020-Q4 | |||||
| SELL | -29.4% | 34.5K | $2M | $31.04 | |
| 2020-Q3 | |||||
| BUY | +0.5% | 48.8K | $1M | $24.56 | |
| 2020-Q2 | |||||
| SELL | -14.0% | 48.6K | $1M | $18.02 | |
| 2020-Q1 | |||||
| BUY | +87.8% | 56.5K | $788000 | $21.40 | |
| 2019-Q4 | |||||
| BUY | NEW | 30.1K | $684000 | $15.44 | |
Insider Trading for ROCKET PHARMACEUTICALS INC
6 Months Insider Sentiment
Buy $34K
Sell $149K
1
Buys
8
Sells
-115K
Net
1
Grants
Largest
$79K
Militello
$34K
Bjork
$22K
Militello
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 02, 2026 | Elisabeth Bjork | Director | BUY | 10.0K | $3.44 | $34K |
| Nov 18, 2025 | Gaurav Shah | CEO | SELL | 6.3K | $2.98 | $19K |
| Nov 18, 2025 | Martin Wilson | General Counsel | SELL | 1.6K | $2.98 | $5K |
| Nov 18, 2025 | John Militello | Vice President of Finance, Treasurer, Principal Accounting Officer | SELL | 1.1K | $2.98 | $3K |
| Nov 18, 2025 | Jonathan David Schwartz | Chief Science & Gene Therapy Officer | SELL | 2.5K | $2.98 | $8K |
| Nov 03, 2025 | Martin Wilson | General Counsel | GRANT | 100.0K | — | — |
| Oct 14, 2025 | John Militello | Vice President of Finance, Treasurer, Principal Accounting Officer | SELL | 19.8K | $3.96 | $79K |
| Oct 14, 2025 | John Militello | Vice President of Finance, Treasurer, Principal Accounting Officer | SELL | 558 | $3.98 | $2K |
| Oct 14, 2025 | John Militello | Vice President of Finance, Treasurer, Principal Accounting Officer | SELL | 3.0K | $3.97 | $12K |
| Oct 14, 2025 | John Militello | Vice President of Finance, Treasurer, Principal Accounting Officer | SELL | 5.5K | $3.96 | $22K |